Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors

AIDS

Volumn 20, Issue 7, 2006, Pages 981-984

  Clark, Shauna A ^a   Shulman, Nancy S ^b   Bosch, Ronald J ^c   Mellors, John W ^a,d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b STANFORD UNIVERSITY   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Drug resistance; Hypersusceptibility; Non nucleoside reverse transcriptase inhibitor; Nucleoside reverse transcriptase inhibitor; Reverse transcriptase

Indexed keywords

DELAVIRDINE; EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; GENE MUTATION; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; PHENOTYPE; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS ISOLATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS RESISTANCE;

CODON; DELAVIRDINE; DRUG RESISTANCE, VIRAL; HIV-1; MUTATION; NEVIRAPINE; OXAZINES; PHENOTYPE; RECOMBINATION, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

EID: 33646376232     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000222069.14878.44     Document Type: Article

References (9)

1. Shulman N, Zolopa AR, Passaro D, Shafer R, Wei H, Katzenstein D, et al. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. AIDS 2001; 15:1125-1132.
2. Whitcomb JM, Huang W, Limoli K, Paxinos E, Wrin T, Skowron G, et al. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: Clinical, phenotypic and genotypic correlates. AIDS 2002; 16:F41-F47.
3. Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 2002; 288:169-180.
4. Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal DN, et al. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS 2002; 16:F33-F40.
5. Katzenstein DA, Bosch RJ, Hellmann N, Wang N, Bacheler L, Albrecht MA. Phenotypic susceptibility and virologic outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs. AIDS 2003; 17:821-830.
6. Shulman NS, Bosch RJ, Mellors JW, Albrecht MA, Katzenstein DA. Genetic correlates of efavirenz hypersusceptibility. AIDS 2004; 18:1781-1785.
7. Girouard M, Diallo K, Marchand B, McCormick S, Gotte M. Mutations E44D and V118I in the reverse transcriptase of HIV-1 play distinct mechanistic roles in dual resistance to AZT and 3TC. J Biol Chem 2003; 278:34403-34410.
8. Mellors JW, Hengameh BZ, Schinazi RF, Roy BM, Hsiou Y, Arnold E, et al. Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob Agents Chemother 1995; 39:1087-1092.
9. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. Selective excision of AZTMP by drug resistant Human Immunodeficiency Virus Reverse Transcriptase. JV 2001; 75 (10):4832-4842.